NAD+ vs NMN vs NR — the precursor conversation

The confusion is real, and it's not your fault. The marketing around these compounds has moved faster than the clinical evidence, and the shorthand has gotten sloppy in ways that matter. They are related, they're not interchangeable, and understanding the difference between them requires a brief detour into cellular biochemistry that turns out to be more interesting than it sounds.

NAD+ — nicotinamide adenine dinucleotide — is not a supplement in the functional sense of something you take and then have more of. It's a coenzyme. It lives inside cells and it's involved in hundreds of enzymatic reactions, most of them having to do with energy metabolism: the conversion of nutrients into ATP, the process by which your cells make usable fuel. It also plays a central role in regulating a class of proteins called sirtuins — which are involved in DNA repair, inflammation control, and cellular stress response — and in activating PARP enzymes, which respond to DNA damage. NAD+ is, in other words, everywhere. It's not a single-function molecule; it's a cellular currency that underlies an enormous range of biological processes.

And it declines with age. This is the fact that kicked off a decade of longevity research and a consumer category worth several billion dollars. By the time you're in your fifties, your NAD+ levels are roughly half what they were in your twenties. The question the researchers were asking — and are still asking — is whether that decline is a cause of aging-related dysfunction or simply a correlate of it. Whether restoring NAD+ levels does what we hope it does, or whether the NAD+ decline is a downstream symptom of something more fundamental. That question is still open.

But here's the immediate practical problem: you can't just swallow NAD+ and have more of it in your cells. Oral NAD+ is a relatively large, charged molecule. It doesn't survive the digestive environment intact, and even if it did, the gastrointestinal cell membrane is not set up to absorb it and deliver it to the intracellular space where it needs to work. Studies on oral NAD+ have shown very limited plasma elevation and minimal intracellular effect. This is not a fringe view — it's the mainstream pharmacological assessment that drove the research toward precursors in the first place.

NMN and NR are precursors. They're molecules that the cell converts into NAD+ through what's called the salvage pathway — a metabolic recycling process by which the cell regenerates NAD+ from components rather than building it from scratch. Think of it like this: NAD+ is the finished building; NMN and NR are different-sized prefabricated panels that can be assembled into it once they get inside.

NR — nicotinamide riboside — sits two enzymatic steps upstream of NAD+. It enters cells via specific nucleoside transporters, gets phosphorylated to NMN by an enzyme called NRK (nicotinamide riboside kinase), and then NMN gets converted to NAD+ by NMNAT enzymes. NMN — nicotinamide mononucleotide — is one step closer: it's already been phosphorylated and requires only the NMNAT step to become NAD+. The difference in position on the pathway matters theoretically, though it's turned out to matter differently than some researchers initially expected.

The researchers who most prominently work in this space have staked out different positions, and the positions are worth understanding because they're not just academic — they reflect genuine disagreements about mechanism.

Charles Brenner, who pioneered NR research and was central to its commercial development, has been NR's most consistent scientific advocate. His argument is essentially that NR is well-characterized, that its absorption and conversion mechanism is proven, and that it reliably raises NAD+ in human blood in controlled trials. The bioavailability evidence for NR is more established than for NMN largely because NR was studied first in rigorous human pharmacokinetic trials and because Brenner's lab produced much of that data. He has also been a persistent skeptic of some of the more expansive longevity claims made around both compounds.

Shin-ichiro Imai at Washington University in St. Louis has been the most prominent researcher arguing for NMN's specific advantages. Imai's mouse studies showed striking effects of NMN on metabolic function, muscle endurance, and several aging biomarkers. His position, and that of his collaborators, is that NMN's additional proximity to NAD+ on the salvage pathway may give it advantages that the NR-to-NMN conversion step can't fully replicate, particularly in tissues where the NRK enzyme is limiting. Imai's 2021 human pilot study, published in Science, showed NMN raised NAD+ in blood and improved muscle insulin sensitivity in older men — a modest but real clinical data point.

David Sinclair at Harvard sits closer to the NMN camp in terms of what he takes personally and what his lab has explored, though his primary research contribution has been on the sirtuin side of the picture rather than the precursor comparison per se. Sinclair's work on SIRT1, SIRT3, and the information theory of aging helped establish why NAD+ availability matters for sirtuins — these proteins require NAD+ as a cofactor, not just as a metabolic input — and he's been a major voice in popularizing the aging-as-NAD+-decline framework in ways that have reached well beyond academic circles.

The transporter question is one of the genuine scientific controversies in this space. A 2019 paper by Imai's group identified a transporter called Slc12a8 that appeared to directly transport NMN into intestinal cells without prior conversion to NR — suggesting that NMN might have a distinct route to bioavailability, not just a stepwise conversion. This was significant because it would mean NMN doesn't need to be dephosphorylated to NR before absorption, which had been the assumed mechanism. Brenner and others have challenged this interpretation, arguing the evidence for Slc12a8 as a functional NMN transporter in humans is not definitive and that most NMN absorption in humans still likely proceeds through NR conversion. The controversy hasn't been fully resolved. The research is ongoing.

What we can say with reasonable confidence: both NR and NMN, taken orally, do raise NAD+ in human blood. This has been shown in multiple human pharmacokinetic studies for NR, and in at least a few trials for NMN including the Imai 2021 study. Blood NAD+ isn't the same as intracellular NAD+ in specific tissues — the measurement you actually want — but it's a reasonable proxy and it's what's feasible to measure in human trials. Both compounds are absorbed. Both compounds are converted. Whether the absolute increase in intracellular NAD+ is meaningfully different between them remains genuinely unclear from the available human data.

There's a third approach that sidesteps the oral bioavailability question entirely: compounded NAD+ administered by injection — subcutaneously, intramuscularly, or intravenously. IV NAD+ infusions deliver the coenzyme directly into the bloodstream, bypassing gastrointestinal degradation and cell membrane transport requirements altogether. The plasma levels achieved with IV NAD+ are not comparable to anything you can get orally. These protocols — typically 500 to 1500 mg over several hours — are not FDA-approved, and the clinical evidence base is different in character from the randomized controlled trials that support NR. But the pharmacological rationale for why they'd produce more dramatic intracellular delivery, at least transiently, is sound. For people asking why some protocols rely on IV rather than oral precursors, this is the answer.

The niacin pathway is also worth a brief mention because it's often left out of this conversation. Nicotinamide — plain niacin — is further upstream in the NAD+ biosynthesis pathway, much cheaper than NMN or NR, and genuinely effective at raising NAD+ levels. The reason it's not the obvious answer is that high-dose niacin has its own side effect profile — principally flushing, and at very high doses, hepatotoxicity — and the dose required to significantly raise NAD+ is substantially higher than what's in a standard B-vitamin supplement. Nicotinamide riboside was partly developed as a way to get NAD+ precursor activity without the niacin side effects. This context matters for calibrating whether the premium price of NMN or NR is justified for a given person's situation.

Where does the evidence stand? At the level of cellular pharmacology — the mechanisms by which NAD+ supports energy metabolism, sirtuin function, and DNA repair — the science is solid and well-replicated. These are not speculative pathways. At the level of NR and NMN raising NAD+ in humans — blood NAD+, at least — the evidence is reasonably good. At the level of specific clinical outcomes in humans: improved metabolic function, muscle health, cognitive performance, reduced aging markers, longevity — the evidence is early, interesting, and far from conclusive. The mouse studies are striking. Mouse lifespan studies, though, have a poor record of translating directly to human outcomes, and the longevity-specific claims remain in the category of plausible hypothesis rather than demonstrated benefit.

The honest framing is that NR and NMN are tools for supporting something real — a coenzyme whose decline is associated with aging-related changes that are real — using a mechanism that is real, toward clinical outcomes that remain to be established at the human scale. The precursor question matters because absorption matters. The NMN-versus-NR debate has not been decisively resolved and may not be for years. And the gap between "we have good mechanistic reasons to expect benefit" and "we have demonstrated that benefit in controlled human trials" is exactly the gap this field is currently trying to close.

What you take from the supplement aisle — if you take anything — should be informed by that honest picture, not the version where every product description implies the longevity question has been answered.